{"id":2349462,"date":"2021-07-21T09:56:49","date_gmt":"2021-07-21T13:56:49","guid":{"rendered":"https:\/\/www.valuewalk.com\/?p=2349462"},"modified":"2021-07-21T09:56:49","modified_gmt":"2021-07-21T13:56:49","slug":"jj-covid-vaccine-sales-2-5-billion-2021","status":"publish","type":"post","link":"https:\/\/www.valuewalk.com\/jj-covid-vaccine-sales-2-5-billion-2021\/","title":{"rendered":"Johnson & Johnson Anticipates Covid Vaccine Sales of $2.5 Billion in 2021"},"content":{"rendered":"

Johnson & Johnson<\/a> (NYSE:JNJ) is expecting its COVID-19 vaccine to reach $2.5 billion in sales this year, despite concerns about the injection\u2019s efficacy against the dreaded Delta variant.<\/p>\n

[soros]<\/p>\n

Q2 2021 hedge fund letters, conferences and more<\/strong><\/em><\/a><\/p>\n

Second Quarter Results<\/h2>\n

On Wednesday, the company released its financial results for the second quarter, beating Wall Street expectations in terms of both earnings and revenue, with the company\u2019s share price \u201cup nearly 1% in premarket trading following the report,\u201d CNBC<\/a> reports.<\/p>\n

According to estimates by Refinitiv, J&J\u2019s adjusted EPS reached $2.48 per share against the Wall Street forecast. Also, out of a $22.21 billion expected revenue, the multinational topped $23.31 billion.<\/p>\n

J&J\u2019s single-shot Covid vaccine<\/a> accounted for $12.59 billion in revenue, which represents a 17.2% year-over-year increase, while its global sales in the quarter hit $164 million.<\/p>\n

\u201cThe company\u2019s consumer unit, which makes products such as Neutrogena face wash and Listerine, generated $3.7 billion in revenue, up 13.3% from a year earlier.\u201d The revenue accrued by the medical device unit grew by 62.7% topping $6.9 billion.<\/p>\n

Joseph Wolk, J&J<\/a> Chief Financial Officer, told CNBC: \u201cWe\u2019ve all realized over the last 18 months just how important good health is and elective isn\u2019t elective forever.\u201d<\/p>\n

What Is to Come<\/h2>\n

In the report, J&J has increased its earnings and revenue guidance for the year, anticipating profit of $9.50 to $9.60 per share after forecasting $9.30 to $9.45 per share.<\/p>\n

Revenue is expected to reach between $92.5 billion and $93.3 billion, \u201ccompared with its prior forecast of $89.3 billion to $90.3 billion.\u201d<\/p>\n

The positive financial results arrive after a study disclosed on Tuesday suggests a lower efficacy of the J&J shot against the Delta and Lambda variants of COVID-19. This has triggered the talk of a booster<\/a> in J&J recipients.<\/p>\n

The study is yet to be reviewed, but disputes a report by the firm stating that the shot is successful against delta, \u201cespecially against severe disease and hospitalization, even eight months after inoculation.\u201d<\/p>\n

Wolk warned that the public should be \u201cguarded\u201d about such results as the study was performed in a lab and \u201cmay not reflect the shot\u2019s performance in a real-world setting.\u201d<\/p>\n

At present, 83% of Covid infections in the U.S. belong to the much-feared Delta variant<\/a>, as informed by the Centers for Disease Control and Prevention.<\/p>\n

\u201cI think it\u2019s probably best for everyone to refer to health officials who have not yet recommended a booster, even for some less duration vaccines out there,\u201d Wolk said.<\/p>\n ","protected":false},"excerpt":{"rendered":"

Johnson & Johnson (NYSE:JNJ) is expecting its COVID-19 vaccine to reach $2.5 billion in sales this year, despite concerns about … Read more<\/a><\/p>\n","protected":false},"author":21832,"featured_media":2126953,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[6640],"tags":[590128,648447],"states":[],"acf":[],"modified_by":"Umair Tariq","_links":{"self":[{"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/posts\/2349462"}],"collection":[{"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/users\/21832"}],"replies":[{"embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/comments?post=2349462"}],"version-history":[{"count":0,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/posts\/2349462\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/media\/2126953"}],"wp:attachment":[{"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/media?parent=2349462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/categories?post=2349462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/tags?post=2349462"},{"taxonomy":"states","embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/states?post=2349462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}